Breaking News, Collaborations & Alliances

PharmaCyte Biotech Closer to Submitting IND

Austrianova completes encapsulation of second manufacturing run of clinical trial product.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PharmaCyte Biotech, a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, is closer to submitting an Investigational New Drug application (IND) to the U.S. Food & Drug Administration (FDA). PharmaCyte said that its partner, Austrianova Singapore, has successfully completed encapsulation of the cells from PharmaCyte’s Master Cell Bank (MCB) in the second of two staggered and back-to-back ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters